CytomX Therapeutics Inc CTMX.OQ CTMX.O is expected to show a fall in quarterly revenue when it reports results on November 6 for the period ending September 30 2025
The South San Francisco California-based company is expected to report a 65.2% decrease in revenue to $11.625 million from $33.43 million a year ago, according to the mean estimate from 8 analysts, based on LSEG data.
LSEG's mean analyst estimate for CytomX Therapeutics Inc is for a loss of 5 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for CytomX Therapeutics Inc is $6.00, about 34.5% above its last closing price of $3.93
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2025 | -0.08 | -0.08 | 0.00 | Beat | 98.7 |
Mar. 31 2025 | 0.12 | 0.12 | 0.27 | Beat | 117.7 |
Dec. 31 2024 | -0.15 | -0.20 | 0.23 | Beat | 217.5 |
Sep. 30 2024 | -0.16 | -0.17 | 0.07 | Beat | 140.7 |
Jun. 30 2024 | -0.12 | -0.14 | -0.08 | Beat | 44.2 |
Mar. 31 2024 | -0.08 | -0.08 | 0.17 | Beat | 305.2 |
Dec. 31 2023 | 0.01 | -0.03 | 0.01 | Beat | 135 |
Sep. 30 2023 | -0.15 | -0.19 | 0.04 | Beat | 121.2 |
This summary was machine generated November 4 at 21:54 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)